Tumor lysis syndrome: Risk factors and treatment;Tumorlysesyndrom: Risikofaktoren und therapie

Wiener Klinische Wochenschrift

Volumn 117, Issue 1-2, 2005, Pages 7-17

  Hörl, Walter H ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Acute renal failure; Allopurinol; Hyperkalemia; Hyperphosphatemia; Hyperuricemia; Rasburicase; Tumor lysis syndrome

Indexed keywords

ALLOPURINOL; RASBURICASE;

ACIDOSIS; ACUTE KIDNEY FAILURE; BONE MARROW SUPPRESSION; HEMODIALYSIS; HUMAN; HYDRATION; HYPERKALEMIA; HYPERPHOSPHATEMIA; HYPERURICEMIA; HYPOCALCEMIA; LYMPHOPROLIFERATIVE DISEASE; REVIEW; RISK FACTOR; SOLID TUMOR; TUMOR LYSIS SYNDROME; URINE PH; URINE VOLUME;

CLINICAL TRIALS; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; RISK ASSESSMENT; RISK FACTORS; TUMOR LYSIS SYNDROME;

EID: 17444367709     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00508-005-0318-y     Document Type: Review

References (151)

1. Bedrna J, Polcák J (1929) Akuter Harnleiterverschluss nach Bestrahlung chronischer Leukämien mit Röntgenstrahlen. Med Klin 25: 1700-1708
2. Salkowski E (1870) Beiträge zur Kenntnis der Leukämie. Arch Pathol Anat 50: 174-210
3. Jugenberg A, Tschotschia K (1931) Neue Ergebnisse zum Verständnis des Leukämieverlaufes. Strahlentherapie 41: 86-100
4. Cohen LF, Balow JE, Magrath IT, Poplack DG, Ziegler JL (1980) Acute tumor lysis syndrome: a review of 37 patients with Burkitt's lymphoma. Am J Med 68: 486-491
5. Altman A (2001) Acute tumor lysis syndrome. Semin Oncol 28 [Suppl 5]: 3-8
6. Jeha S (2001) Tumor lysis syndrome. Semin Hematol 38 [Suppl 10]: 4-8
7. Flombaum CD (2000) Metabolic emergencies in the cancer patient. Semin Oncol 27: 322-334
8. Jasek AM, Day HJ (1994) Acute spontaneous tumor lysis syndrome. Am J Hematol 47: 128-131
9. Sewani HH, Rabatin JT (2002) Acute tumor lysis syndrome in a patient with mixed small cell and non-small cell tumor. Mayo Clinic Proc 77: 722-728
10. Kalemkerian GP, Darwish B, Varteraisan ML (1997) Tumor lysis syndrome in small cell carcinoma and other solid tumors. Am J Med 103: 363-367
11. Persons DA, Garst J, Vollmer R, Crawford J (1998) Tumor lysis syndrome and acute renal failure after treatment of non-cell lung carcinoma with combination irinotecan and cisplatin. Am J Clin Oncol 21: 425-429
12. Zigrossi P, Brustia M, Bobbio F, Campanini M (2001) Flare and tumor lysis syndrome with atypical features after letrozole therapy in advanced breast cancer. A case report. Ann Ital Med Int 16: 112-117
13. Rostom AY, El-Hussainy G, Kandil A, Allam A (2000) Tumor lysis syndrome following hemi-body irradiation for metastatic breast cancer. Ann Oncol 11: 1349-1351
14. Sklarin NT, Markham M (1995) Spontaneous recurrent tumor lysis syndrome in breast cancer. Am J Oncol 18: 71-73
15. Stark ME, Dyer MC, Coonley CJ (1987) Related fatal acute tumor lysis syndrome with metastatic breast carcinoma. Cancer 60: 762-764
16. Cech P, Block JB, Cone LA, Stone R (1986) Tumor lysis syndrome after tamoxifen flare. N Engl J Med 315: 263-264
17. Drakos P, Bar-Ziv J, Catane R (1994) Tumor lysis syndrome in nonhematological malignancies. Am J Clin Oncol 17: 502-505
18. Hain RD, Rayner L, Weitzman S, Lorenzana A (1994) Acute tumor lysis syndrome complicating treatment of stage IVS neuroblastoma in infants under six months. Med Pediatr Oncol 23: 136-139
19. Tomlinson GC, Solberg LA Jr (1984) Acute tumor lysis syndrome with metastatic medulloblastoma. A case report. Cancer 53: 1783-1785
20. Ykoi K, Miyazawa N, Kano Y, Akutsu M, Mori K, Tominaga K, et al (1997) Tumor lysis syndrome in invasive thymoma with peripheral blood T-cell lymphocytosis. Am J Clin Oncol 20: 86-89
21. Khan J, Broadbent VA (1993) Tumor lysis syndrome complicating treatment of widespread metastatic abdominal rhabdomyosarcoma. Pediatr Hematol Oncol 10: 151-155
22. Khalil A, Chammas M, Shamseddine A, Seoud M (1998) Fatal acute tumor lysis syndrome following treatment of vulvar carcinoma: case report. Eur J Gynaecol Oncol 19: 415-416
23. Shamseddine AI, Khalil AM, Wehbeh MH (1993) Acute tumor lysis syndrome with squamous cell carcinoma of the vulva. Gynecol Oncol 51: 258-260
24. Dirix LY, Prove A, Becquart D, Wouters E, Vermeulen P, Van Oosterom A (1991) Tumor lysis syndrome in a patient with metastatic Merkel cell carcinoma. Cancer 67: 2207-2210
25. Pentheroudakis G, O'Neill VJ, Vasey P, Kaye SB (2001) Spontaneous acute tumour lysis syndrome in patients with metastatic germ cell tumours. Report of two cases. Support Care Cancer 9: 554-557
26. Barton JC (1989) Tumor lysis syndrome in nonhematopoietic malignancies. Cancer 64: 738-740
27. Bilgrami SF, Fallon BG (1993) Tumor lysis syndrome after combination chemotherapy for ovarian cancer. Med Pediatr Oncol 21: 521-524
28. Habib GS, Saliba WR (2002) Tumor lysis syndrome after hydrocortisone treatment in metastatic melanoma: a case report and review of the literature. Am J Med Sci 323: 155-157
29. Stoves J, Richardson D, Patel H (2001) Tumor lysis syndrome in a patient with metastatic melanoma treated with biochemotherapy. Nephrol Dial Transplant 16: 188-189
30. Sorscher SM (2004) Tumor lysis syndrome following docetaxel therapy for intensive metastatic prostate cancer. Cancer Chemother Pharmacol 54: 191-192
31. Crittenden DR, Ackerman GL (1977) Hyperuricemic acute renal failure in disseminated carcinoma. Arch Intern Med 137: 97-99
32. Alkhuja S, Ulrich HJ (2002) Acute renal failure from spontaneous acute tumor lysis syndrome: a case report. Ren Fail 24: 227-232
33. Feld J, Mehta H, Burkes RL (2000) Acute spontaneous tumor lysis syndrome in adenocarcinoma of the lung: a case report. Am J Clin Oncol 23: 491-493
34. Agha-Razii M, Amyot SL, Pichette V, Cardinal J, Ouimet D, Leblanc M (2000) Continuous veno-venous hemodiafiltration for the treatment of spontaneous tumor lysis syndrome complicated by acute failure and severe hyperuricemia. Clin Nephrol 54: 59-63
35. Hsu HH, Chan YL, Huang CC (2004) Acute spontaneous tumor lysis presenting with hyperuricemic acute renal failure: clinical features and therapeutic approach. J Nephrol 17: 50-56
36. Hsu HH, Huang CC (2004) Acute spontaneous tumor lysis in anaplastic large T-cell lymphoma presenting with hyperuricemic acute renal failure. Int J Hematol 79: 48-51
37. Baeksgaard L, Sorensen JB (2003) Acute tumor lysis syndrome in solid tumors - a case report and review of the literature. Cancer Chemother Pharmacol 51: 187-192
38. Plotkin D, Lechner JJ, Jung WE, Rosen PJ (1978) Tamoxifen flare in advanced breast cancer. JAMA 240: 2644-2646
39. Tanvetyanon T, Choudhury AM (2004) Fatal acute tumor lysis syndrome, hepatic encephalopathy and flare phenomenon following combined androgen blockade. J Urol 171: 1627
40. Chasty RC, Liu-Yin JA (1993) Acute tumor lysis syndrome. Br J Hosp Med 49: 488-492
41. Tsimberidou AM, Keating MJ (2005) Hyperuricemic syndromes in cancer patients. Contrib Nephrol 147: 47-60
42. Simmons ED, Somberg KA (1991) Acute tumor lysis syndrome after intrathecal methotrexate administration. Cancer 67: 2062-2065
43. Benekli M, Gullu ICH, Savas MC, Kadayifci A, Altuntag MK, Tekuzman G, et al (1996) Acute tumor lysis syndrome following intrathecal methotrexate. Leuk Lymphoma 22: 361-363
44. Castro MP, Van Auken J, Spencer-Cisak P, Legha S, Sponzo RW (1999) Acute tumor lysis syndrome associated with concurrent biochemotherapy of metastatic melanomea. Cancer 85: 1055-1059
45. Busam KJ, Wolchok J, Jungbluth AA, Chapman P (2004) Diffuse melanosis after chemotherapy-induced tumor lysis syndrome in a patient with metastatic melanoma. J Cutan Pathol 31: 274-280
46. Ralph R, Adrogue HE, Dolson G, Ramanathan V (2004) Acute renal failure due to tumor lysis syndrome in a HIV seropositive patient with Castelman's disease. Nephrol Dial Transplant 19: 1937
47. Lee KD, Lee KW, Choi IS, Yoon SS, Park S, Kim BK, et al (2004) Multicentric Castleman's disease complicated by tumor lysis syndrome. Ann Hematol 83: 722-725
48. Trobough-Lotrario AD, Liang X, Janik JS, Lovell MA, Odom LF (2004) Difficult diagnostic and therapeutic cases. Case 2. Thymoma and tumor lysis syndrome in an adolescent. J Clin Oncol 22: 955-957
49. Holland P, Holland NH (1968) Prevention and management of acute hyperuricemia in childhood leukemia. J Pediatr 72: 358-336
50. Krakoff IH, Murphy ML (1968) Hyperuricemia in neoplastic disease in children: Prevention with allopurinol, a xanthine oxidase inhibitor. Pediatrics 41: 52-56
51. Arseneau JC, Bagley CM, Anderson T, Canellos GP (1973) Hyperkalaemia, a sequel to chemotherapy of Burkitt's lymphoma. Lancet 1: 10-14
52. Arseneau JC, Canellos GP, Banks PM, Berard CW, Gralnick HR, DeVita VT Jr (2975) American Burkitt's lymphoma: A clinicopathologic study of 30 cases. I. Clinical factors relating in prolonged survival. Am J Med 58: 314-321
53. Rieselbach RE, Steele TH (1975) Intrinsic renal disease leading to abnormal urate excretion. Nephron 14: 81-87
54. Fleming DR, Doukas MA (1992) Acute tumor lysis syndrome in hematologic malignancies. Leuk Lymphoma 8: 315-318
55. Razis E, Arlin Z, Ahmed T, Feldman EJ, Puccio C, Cook P, et al (1994) Incidence and treatment of tumour lysis syndrome in patients with acute leukaemia. Acta Haematol 91: 171-174
56. Jones DP, Mahmoud H, Chesney RW (1995) Tumor lysis syndrome: pathogenesis and management. Pediatr Nephrol 9: 206-212
57. Cany L, Fitoussi O, Boiron JM, Marit G (2002) Tumor lysis syndrome at the beginning of thalidomide therapy for multiple myeloma. J Clin Oncol 20: 2212
58. Fuente N, Mane IM, Barcelo R, Munoz A, Perez-Hoyos T, Lopez-Vivanco G (2004) Tumor lysis syndrome in a multiple myeloma treated with thalidomide. Ann Oncol 15: 537
59. Van de Kerkhof JJ, Peters WG, Visser J, Creemers GJ (2001) Acute tumor lysis syndrome in a patient with multiple myeloma treated with dexamethasone monotherapy. Neth J Med 59: 83-85
60. Passas AB, Desikan KR, Siegel D, Golper TA, Munshi NC, Barlogie B, et al (1999) Tumor lysis syndrome complicating high-dose treatment in patients with multiple myeloma. Br J Haematol 105: 938-941
61. Mehta J, Jakob C, Singhal S, Stadtmauer E, Richardson P, Vesole D, et al (2003) Bortezomib causes tumor lysis syndrome in approximately 1% of patients with myeloma. Blood 102 [Suppl 2]: 386b
62. Terpos E, Politou M, Rahemtulla A (2004) Tumour lysis syndrome in multiple myeloma after bortezomib (VELCADE) administration. J Cancer Res Clin Oncol 130: 623-625
63. Montalban C, Liano F, Aguilera A (1994) Tumour lysis syndrome after treatment of chronic lymphocytic leukaemia with fludarabine. Postgrad Med J 70: 651-652
64. Killick S, Mercieca J, Nandi A, Behrens J (1997) Fludarabine-induced tumour lysis in low-grade non-Hogkin's lymphoma. Clin Lab Haematol 19: 79-80
65. List AF, Kummet TD, Adams JD, Chun HG (1990) Tumor lysis syndrome complicating treatment of chronic lymphocytic leukemia with fludarabine phosphate. Am J Med 89: 388-390
66. Fenchel K, Bergmann L, Wijermans P, Engert A, Pralle H, Mitrou PS, et al (1995) Clinical experience with fludarabine and its immunosuppressive effects in pretreated chronic lymphocytic leukemias and low-grade lymphomas. Leuk Lymphoma 18: 485-492
67. Nakhoul F, Green J, Abassi ZA, Carter A (1996) Tumor lysis syndrome induced by fluradabine monophosphate. A case report. Eur J Haematol 56: 254-255
68. Cheson BD, Frame JN, Vena D, Quashu N, Sorensen JM (1998) Tumor lysis syndrome: An uncommon complication of fludarabine therapy of chronic lymphocytic leukemia. J Clin Oncol 16: 2313-2320
69. Hussain K, Mazza JJ, Clouse LH (2003) Tumor lysis syndrome following fludarabine therapy for chronic lymphocytic leukemia: Case report and review of the literature. Am J Hematol 72: 212-215
70. Grever MR, Kopecky KJ, Coltman CA, Files JC, Greenberg BR, Button JJ, et al (1988) Fluradabine monophosphate: a potentially useful agent in chronic lymphocytic leukemia. Nouv Rev Fr Hematol 30: 457-459
71. Keating MJ, Kantarjian H, Talpaz M, Redman J, Koller C, Barlogie B, et al (1989) Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood 74: 19-25
72. Bergmann K, Fenchel K, Jahn B, Mitrou PS, Hoelzer D (1993) Immunosuppressive effects and clinical response of fludarabine in refractory chronic lymphocytic leukemia. Ann Oncol 4: 371-375
73. Cannon LM, Spilove L, Rhodes R, Garfinkel H, Pezzimenti J (1993) Acute tumor lysis syndrome complicating fludarabine treatment of prolymphocytic leukemia. Conn Med 57: 651-654
74. Ramachandran A, Majumdar G (2004) Acute tumor lysis syndrome after oral fludarabine in a patient with chronic lymphocytic leukaemia. Hematol J 5: 528-529
75. Dizdar O, Yurekli BS, Purnak T, Aksu S, Haznedaroglu IC (2004) tumor lysis syndrome associated with fludarabine treatment of chronic lymphocytic leukemia. Ann Pharmacother 38: 1319-1320
76. Kikuchi T, Miyata A, Fujii S, Kikuchi T (2003) Acute myelogenous leukemia complicated with severe tumor syndrome after a single day of idarubicin/cytarabine chemotherapy. Rinsho Ketsueki 44: 1113-1116
77. Kurt M Eren OO, Engin H, Guler N (2004) Tumor lysis syndrome following a single dose of capecitabine. Ann Pharmacother 38: 902
78. Thomas MR, Robinson WA, Mughal TI, Glode LM (1984) Tumor lysis syndrome following VP-16-213 in chronic myeloid leukemia in blast crisis. Am J Hematol 16: 185-188
79. Dann EJ, Gillis S, Polliack A, Okon E, Rund D, Rachmilewitz EA (1993) Brief report: Tumor lysis syndrome following treatment with 2- chlorodeoxyadenosine for refractory chronic lymphotic leukemia. N Engl J Med 329: 1547-1548
80. Castro MP, Van Auken J, Spencer-Cisak P, Legha S, Sponzo RW (1999) Acute tumor lysis syndrome associated with concurrent biochemistry of metastatic melanoma. Cancer 85: 1055-1059
81. Coutinho AK, de O Santos M, Pinczowski H, Feher O, del Giglio A (1997) Tumor lysis syndrome in a case of chronic lymphocytic leukemia induced by high-dose corticosteroids. Am J Hematol 54: 85-86
82. Malik IA, Abubakar S, Alam F, Khan A (1994) Dexamethasone-induced tumor lysis syndrome in high-grade non-Hodgkin's lymphoma. South Med J 87: 409-411
83. Sparano J, Ramirez M, Wiernik PH (1990) Increasing recognition of corticosteroid-induced tumor lysis syndrome in non-Hodgkin's lymphoma. Cancer 65: 1072-1073
84. Dillman RO (1999) Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy. Cancer Metastasis Rev 18: 465-471
85. Byrd JC, Waselenko JK, Maneatis TJ, Ward FT, Monaham BP, Sipe MA, et al (1999) Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: Association with increased infusion-related side effects and rapid blood tumor clearance. J Clin Oncol 17: 791-795
86. Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A (1999) Cytokine-release syndrome in patients with B-cell chronic lymphotic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 94: 2217-2224
87. Kunkel L, Wong A, Maneatis T, Nickas J, Brown T, Grillo-Lopez A, et al (2000) Optimizing the use of rituximab for treatment of B-cell non-Hodgkin's lymphoma: A benefit-risk update. Semin Oncol 27: 53-61
88. Coiffer B, Mounier N, Bologna S, Ferme C, Tilly H, Sonet A, et al (2003) Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: Results of the GRAALI (Groupe d'Etude des Lymphoms de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study. J Clin Oncol 21: 4402-4406
89. Minasian LM, Szatrowski TP, Rosenblum M, Steffens T, Morrison ME, Chapman PB, et al (1994) Hemorrhagic tumor necrosis during a pilot trial of tumor necrosis factor-alpha and anti-GD3 ganglioside monoclonal antibody in patients with metastatic melanoma. Blood 83: 56-64
90. Czuczman MS, Strauss DJ, Divgi CR, Graham M, Garin-Chesa P, Finn R, et al (1993) Phase I dose-escalation trial of iodine 131-labeled monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma. J Clin Oncol 11: 2021-2029
91. Fer MF, Bottino GC, Sherwin SA, Hainsworth JD, Abrams PG, Foon KA, et al (1984) Atypical tumor lysis syndrome in a patient with T-cell lymphoma treated with recombinant leukocyte interferon. Am J Med 77: 953-956
92. Fleming DR, Henslee-Downey PJ, Coffey CW (1991) Radiation induced acute tumor lysis syndrome in the bone marrow transplant setting. Bone Marrow Transplant 8: 235-236
93. Yamazaki H, Hanada M, Horiki M, Kuyama J, Sato T, Nishikubo M, et al (2004) Acute tumor lysis syndrome caused by palliative radiotherapy patients with diffuse large B-cell lymphoma. Radiat Med 22: 52-55
94. Annemans L, Moeremans K, Lamotte M, Garcia Conde J, van den Berg H, Myint H, et al (2003) Incidence, medical recource utilization and costs of hyperuricemia and tumor lysis syndrome in patients with acute leukemia and non-Hodgkin's lymphoma in four European countries. Leuk Lymphoma 44: 77-83
95. Seidemann K, Meyer U, Jansen P, Yakisan E, Rieske K, Fuhrer M, et al (1998) Impaired renal function and tumor lysis syndrome in pediatric patients with non-Hodgkin's lymphoma and B-ALL. Observations from the BFM-tirlas. Klein Pädiatr 210: 279-284
96. rd, Wyatt RJ, McKay CR Murphy SB (1988) Acute renal failure at onset of therapy for advanced stage Burkitt lymphoma and B cell acute lymphoblastic lymphoma. Pediatrics 82: 863-869
97. Sullivan MP, Ramirez I (1985) Curability of Burkitt's lymphoma with high-dose cyclophosphamide-high-dose methotrexate therapy and intrathecal chemoprophylaxis. J Clin Oncol 3: 627-636
98. Thomas DA, Cortes J, O'Brien S, Pierce S, Faderl S, Albitar M, et al (1999) Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia. J Clin Oncol 17: 2461-2470
99. Wossmann W, Schrappe M, Meyer U, Zimmermann M, Reiter A (2003) Incidence of tumor lysis syndrome in children with advanced stage Burkitt's lymphoma/leukemia before and after introduction of prophylactic use of urate oxidase. Ann Hematol 82: 160-165
100. Platte C, Sakiroglu C, Ansoborlo S, Baruchel A, Plouvier E, Pacquement H, et al (2002) Societe Francaise d'Oncologie Pediatrique: Urate oxidase in the prevention and treatment of metabolic complications in patients with B cell lymphoma and leukemia, treated in the Societe Française d'Oncologie Pediatrique LMB89 protocol. Ann Oncol 13: 789-795
101. Arrambide K, Toto RD (1993) Tumor lysis syndrome. Semin Nephrol 31: 273-280
102. Vachvanichsanong P, Maipang M, Dissaneewate P, Wongchanchailert M, Laosombat V (1995) Severe hyperphosphatemia following acute tumor lysis syndrome. Med Pediatr Oncol 24: 63-66
103. Thette L, Oster JR, Singer I, Bourgoignie JJ, Fishman LM, Roos BA (1995) Review of the literature: Severe hyperphosphatemia. Am J Med Sci 310: 167-174
104. Abramson EC, Gajardo H, Kukreja SC (1987) Acute tumor lysis syndrome in prolymphocytic leukemia. Arch Intern Med 147: 375-376
105. Kalémkerian GP, Darwish B, Barterasian ML (1997) Tumor lysis syndrome in small cell carcinoma and other solid tumors. Am J Med 103: 363-367
106. Conger JD (1990) Acute uric acid nephropathy. Med Clin North Am 74: 859-871
107. Hsu HH, Chan YL, Huang CC (2004) Acute spontaneous tumor lysis presenting with hyperuricemic acute renal failure: clinical features and therapeutic approach. J Nephrol 17: 50-56
108. Kelton J, Kelly WN, Holmes EW (1978) A rapid method for the diagnosis of acute uric acid nephropathy. Arch Intern Med 138: 612-615
109. Cairo MS (2002) Prevention and treatment of hyperuricemia in hematological malignancies. Clin Lymphoma 3 [Suppl 1]: S26-S31
110. Ronco C, Inguaggiato P, Bordoni V, Del Cal M, Bonello M, Andrikos E, et al (2005) Rasburicase therapy in acute hyperuricemia and renal Dysfunction. Contr Nephrol 147: 115-123
111. Gomez GA, Han T (1987) Acute tumor lysis syndrome in prolymphocytic leukemia. Arch Intern Med 147: 375-376
112. McCroskey RD, Mosher DF, Spencer CD, Prendergast E, Longo WL (1990) Acute tumor lysis syndrome and treatment response in patients treated for refractory chronic lymphocytic leukemia with short-course, high-dose cytosine arabinoside, cisplatin, and etoposide. Cancer 66: 246-250
113. Lorigan PC, Woodings PL, Morgenstern GR, Scarffe JH (1996) Tumour lysis syndrome, case report and review of the literature. Ann Oncol 7: 631-636
114. Sondheimer JH, Migdal SD (1987) Toxic nephropathie. Crit Care Clin 3: 883-907
115. Sallan S (2001) Management of acute tumor lysis syndrome. Semin Oncol 28 [Suppl 5]: 9-12
116. Cairo MS, Bishop M (2004) Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol 127: 3-11
117. Jeha S, Pui CH (2005) Recombinant urate oxidase (rasburicase) in the prophylaxis and treatment of tumor lysis syndrome. Contrib Nephrol 147: 69-79
118. th edn. McGraw-Hill, New York, pp 271-283
119. Wilcox WR, Khalaf A, Weiberger A, Kippen I, Klinenberg JR (1972) Solubility of uric acid and monosodium urate. Med Biol Eng 10: 522-531
120. Conger JD, Falk SA, Guggenheim SJ, Burke TJ (1976) A micropuncture study of the early phase of acute urate nephropathy. J Clin Invest 58: 681-689
121. Monballyu J, Zachee P, Verberckmoes R, Boogaerts MA (1984) Transient acute renal failure due to to tumor-lysis-induced severe phosphate loead in a Burkitt's lymphoma. Clin Nephrol 22: 47-50
122. Conger JD, Falk SA (1977) Intrarenal dynamics in the pathogenesis and prevention of acute urate nephropathy. J Clin Invest 59: 786-793
123. De Conti RC, Calabresi P (1966) Use of allopurinol for prevention and control of hyperuricemia in patients with neoplastic disease. N Engl J Med 274: 481-86
124. Smalley RV, Guaspari A, Haase-Statz S, Anderson SA, Cedarberg D, Hohneker JA (2000) Allopurinol intravenous use for prevention and treatment of hyperuricemia. J Clin Oncol 18: 1758-1763
125. Moriwaki Y, Yamamoto T, Higashino K. Enzymes involved in purine metabolism - a review of histochemical localization and functional implications. Histol Histopathol 14: 1321-1340, 1999
126. Wu XW, Lee CC, Muzny DM, Caskey CT (1989) Urate oxidase: primary structure and evolutionary implications. Proc Natl Acad Sci USA 86: 9412-9416
127. Wu XW, Munzy DM, Lee CC, Caskey CT (1992) Two independent mutational events in the loss of urate oxidase during hominoid evolution. J Mol Evol 34: 78-84
128. Yeldani AV, Yeldani V, Kumar S, Murthy CV, Wang XD, Alvares K, et al (1991) Molecular evolution of the urate oxidase-encoding gene in hominoid primates. Nonsense mutations. Gene 109: 281-284
129. Ames BN, Cathcart R, Schwiers E, Hochstein P (1981) Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci USA 78: 6858-6862
130. Scott GS, Hooper DC (2001) The role of uric acid in protection against peroxynitrite-mediated pathology. Med Hypotheses 56: 95-100
131. Pui CH, Relling MV, Lascombes F, Harrison PL, Struxiano A, Mondesir JM, et al (1997) Urate oxidase in prevention and treatment of hyperuricaemia associated with lymphoid malignancies. Leukaemia 11: 1813-1816
132. Navolanic PM, Pui CH, Larson RA, Mishop MR, Pearce TE, Cairo MS, et al (2003) Elitek-rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas. Leukemia 17: 499-514
133. Davidson MB, Thakkar S, Hix JK, Bhandarkar ND, Wong A, Schreiber MJ (2004) Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. Am J Med 116: 546-554
134. Fraisse L, Bonnet MC, De Farcy JP, Agut C, Dersigny D, Bayol A (2002) A colorimetric 96-well microtiter plate assay for the determination of urate oxidase activity and its kinetic parameters. Anal Biochem 309: 173-179
135. Pui CH (2002) Rasburicase: a potent uricolytic agent. Expert Opin Pharmacother 3: 433-452
136. Pui CH, Mahmoud H, Wiley JM, Woods GM, Leverger G, Camitta B, et al (2001) Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. J Clin Oncol 19: 697-704
137. Goldman SC, Holcenberg JS, Finklestein JZ, Hutchinson R, Kreissman S, Johnson FL, et al (2001) A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk of tumor lysis. Blood 97: 2998-3003
138. Macfarlane RJ, McCully BJ, Fernandez CV (2004) Rasburicase prevents tumor lysis syndrome despite extreme hyperleukocytosis. Pediatr Nephrol 19: 924-927
139. Wolf G, Hegewisch-Becker S, Hossfeld DK, Stahl RAK (1999) Hyperuricaemia and renal insufficiency associated with malignant disease: urate oxidase as an efficient therapy? Am J Kidney Dis 34: 20 E
140. Stapleton F, Strother D, Roy III S, Wyatt R, McKay C, Murphy S (1988) Acute renal failure at onset of therapy for advanced stage Burkitt lymphoma and B cell acute lymphoblastic leukemia. Pediatrics 82: 863-869
141. Leach M, Parsons RM, Reilly JT, Winfield DA (1998) Efficacy of urate oxidase (uricozyme) in tumour lysis induced urate nephropathy. Clin Lab Haematol 20: 169-172
142. Pui CH (2002) Rasburicase: a potent uricolytic agent. Expert Opin Pharmacother 3: 433-452
143. Pui CH, Jeha S, Irwin D, Camitta B (2001) Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: results of a compassionate-use trial. Leukemia 15: 1505-1509
144. Van den Berg H, Reintsema AM (2004) Renal tubular damage in rasburicase: risks of alkalinisation. Ann Oncol 15: 175-176
145. Pui CH (2001) Urate oxidase in the prophylaxis or treatment of hyperuricemia: the United States Experience. Semin Hematol 38 [Suppl 10]: 13-21
146. Arnold TM, Reuter JP, Delman BS, Shanholtz CB (2004) Use of single-dose rasburicase in an obese female. Ann Pharmacother 38: 1428-1431
147. Krych M, Dreyling M, Kneba M, Hoelzer D, Hiddemann W, Hallek M (2004) Prophylaxe und differenzielle Therapie des Tumorlysesyndroms. Dtsch Med Wochenschr 129: 1440-1445
148. Ribeiro RC, Pui CH (2003) Recombinant urate oxidase for prevention of hyperuricemia and tumor lysis syndrome in lymphoid malignancies. Clin Lymphoma 3: 225-232
149. Zaidi SZA, Aljurf M (2004) Is rasburicase needed for prevention of tumor lysis syndrome during treatment of less aggressive hematolymphoid malignancies? J Clin Oncol 22: 3430-3431
150. Hauser P, Oberbauer R (2002) Tubular apoptosis in the pathophysiology of renal disease. Wien Klin Wochenschr 114: 671-677
151. Saccente SL, Kohaut EC, Berkow RL (1995) Prevention of tumor lysis syndrome using continuous veno-venous hemofiltration. Pediatr Nephrol 9: 569-573